STOCK TITAN

Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Core One Labs Inc. (OTC: CLABF) is exploring investment and acquisition opportunities with major pharmaceutical companies. CEO Joel Shacker emphasizes that as research on psychedelics for treating mental health issues progresses, the market for these drugs is expanding, prompting pharmaceutical consolidation. Core One is innovating in psychedelic medicine, holding multiple patents for psilocybin production and formulations targeting mental health disorders. Additionally, the company manages four medical clinics with over 275,000 patients to advance psychedelic-based treatments.

Positive
  • Exploring acquisition opportunities with pharmaceutical companies could enhance market position.
  • Holds multiple patents for psilocybin production systems and pharmaceutical formulations.
  • Management of four medical clinics with a large patient database could facilitate treatment rollout.
Negative
  • None.

VANCOUVER, British Columbia, March 19, 2022 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the “Company” or “Core One”) announces that following its recently announced developments it is actively working to investigate investment and potential takeover opportunities by strategic psychedelics or pharmaceutical companies.

Acquisition or investment by a major pharmaceutical company could be mutually beneficial. As more research comes to light regarding the use of psychedelics to treat depression, addiction, as well as other mental health and cognitive disorders, the market size for psychedelic drugs will increase, and large pharmaceutical companies could look to consolidate the industry to ensure they have a strong drug pipeline in the future,” stated Joel Shacker, Core One CEO.

About Core One Labs Inc.

Core One Labs is a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology.

The Company has a multi-faceted business approach and incorporates several complementary lines of businesses and units in establishing itself as an industry leader in the rapidly growing and emerging psychedelics market space.

Core One, through its wholly owned subsidiary Vocan Biotechnologies Inc., has developed and filed for patent protection of a proprietary psilocybin production system using engineered bacteria. It is also the holder of 4 provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental health disorders, under its 100% owned subsidiary Akome Biotech Ltd., and 3 provisional patents under its other 100% owned subsidiary, Awakened Biosciences Inc., for additional synthetic technologies for psilocybin and psilocin production methods.

In addition to the development of psychedelics and psychedelic compounds, Core One holds an interest in four medical clinics which maintain a combined database of more than 275,000 patients. Through its clinics the Company intends to integrate a roll out of its intellectual property related to psychedelic technologies and participate in the advancement of psychedelic-based treatments for mental health disorders.

Core One Labs Inc.

Joel Shacker
Chief Executive Officer

FOR MORE INFORMATION, PLEASE CONTACT:
info@core1labs.com
1-866-347-5058

Cautionary Disclaimer Statement:
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions, and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things: risks and uncertainties relating to the Company’s limited operating history and the need to comply with strict regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offence to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One does not have any direct or indirect involvement with illegal selling, production, or distribution of psychedelic substances in jurisdictions in which it operates. While Core One believes psychedelic substances can be used to treat certain medical conditions, it does not advocate for the legalization of psychedelics substances for recreational use. Core One does not deal with psychedelic substances, except within laboratory and clinical trial settings conducted within approved regulatory frameworks.


FAQ

What strategic opportunities is Core One Labs Inc. exploring?

Core One Labs Inc. is investigating acquisition and investment opportunities with major pharmaceutical companies to strengthen its market position in the psychedelic industry.

How many patents does Core One Labs hold related to psychedelics?

Core One Labs holds several patents, including four provisional patents for psilocybin production and related pharmaceutical formulations.

What is the role of Core One's medical clinics?

Core One's clinics manage a database of over 275,000 patients, which they intend to leverage for advancing psychedelic-based treatments.

What is the market potential for psychedelics according to Core One Labs?

Core One Labs believes that ongoing research into psychedelics for treating mental health disorders will significantly expand the market for these drugs.

CORE ONE LABS INC

OTC:CLABF

CLABF Rankings

CLABF Latest News

CLABF Stock Data

7.44M
46.70M
0.3%
Biotechnology
Healthcare
Link
United States of America
Vancouver